Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts.
Due to the ever-increasing number of immunocompromised patients, both localised and life-threatening systemic fungal infections are on the increase. Conventional treatment is of limited help, not in the least due to a less optimum benefit-to-risk ratio. Moreover, emerging pathogens with reduced antimicrobial susceptibility and the development of resistance in Candida albicans form a new challenge. Fortunately, conventional antimycotics have been improved and entirely new ones are on the horizon as well as alternative approaches such as immunoreconstitution.
Bastert
J
J
Klinik und Poliklinik für Dermatologie und Allergologie der Ludwig-Maximilians-Universitat München, Frauenlobstr. 9-11, 80337, München, Germany.
Schaller
M
M
Korting
H C
HC
Evans
E G
EG
D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015195:Drug Design; D004352:Drug Resistance, Microbial; D005658:Fungi / Q000187:drug effects*; D006801:Humans; D016867:Immunocompromised Host; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology
D000935:Antifungal Agents